Semaglutide

Adipotide's dose-limiting toxicity is renal, and semaglutide's dehydration and vomiting are a common route to acute kidney injury, so the two stack risk on the same organ.

Both act on the area postrema and both are dose-limited by nausea, so starting them together stacks the one side effect most likely to make someone quit either drug.

CagriSema already contains semaglutide at 2.4mg, the maximal weight-management dose, so adding more is a straight overdose of the GLP-1 component.

Clenbuterol shifts potassium into cells while semaglutide's GI losses remove it from the body, two different routes to the same low reading on a heart that is already running fast.

Two GLP-1 receptor agonists at the same receptor, one daily and one weekly, which in practice only comes up as a badly handled switch between them.

Both carry GLP-1 agonism, but MariTide's 21 day half-life means the overlap when switching lasts weeks rather than days.

Retatrutide already contains full GLP-1 agonism, so adding semaglutide stacks the GI and pancreatic risk without touching the GIP or glucagon arms that make retatrutide stronger.

Semaglutide slows gastric emptying and drives weight loss, and both effects destabilise a levothyroxine dose that was correct before the GLP-1 started.

GLP-1 agonists are the only PED-adjacent compounds that actively lower blood pressure, so an antihypertensive that was correctly dosed before the weight loss frequently becomes too much during it.

These are alternatives, not partners: tesofensine's niche is people who cannot tolerate GLP-1 nausea, and running both trades that GI burden for a cardiovascular one on top of it.

Running both is a GLP-1 overdose with extra steps: tirzepatide already contains full GLP-1 agonism, so the only thing semaglutide adds is more of the receptor that causes the nausea.

Both accelerate weight loss and both cost lean tissue, so combining them pushes the rate past the point where muscle can be preserved.